"Aberrant condensates as drug-targets for cancer"
Deadline: 04/03/2026
Scientific-Disciplinary Group
05/BIOS-08 - Molecular Biology
Description
The research project exploits biomolecular condensates for cancer-treatment via modulating the properties of aberrant protein droplets, caused by somatic mutations. It will target protein interactions, which underlie formation of aberrant condensates via small molecules or antibodies to restore normal function. As more than half of the cancer-driver proteins cannot be targeted using traditional, structure-based methods this work will provide a novel approach via targeting the collective behaviour of proteins in the condensed state. The research aims to demonstrate that effective in cancer treatment can be achieved via modulating the properties of aberrant biomolecular condensates, caused by somatic cancer mutations. The project aims to provide a proof-of- principle that condensates can be used as targets in drug development and are effective against different types of cancers.
Job posting website
Number of positions
1
Funding body
Università degli Studi di Padova
How to apply
View the original posting on the MUR website: Go to MUR website